Zobrazeno 1 - 10
of 31
pro vyhledávání: '"L, Arias García"'
Autor:
M Chaparro, M García Donday, S Rubio, C Calviño Suarez, A Nuñez Ortiz, M Figueira, S Marín Pedrosa, M Rivero, A Fernández-Clotet, L Madero, M T Diz-Lois Palomares, I Pérez-Martínez, A Ruiz-Cerulla, M Arroyo, M Piqueras, C Suarez Ferrer, M Aguas, M Calvo Moya, I Guerra, P López Serrano, J M Vázquez Morón, L Arias García, M J Casanova, J M Huguet, G Valldosera Gomis, B Zúñiga de Mora-Figueroa, R Armesto, P Martínez Montiel, I Rodríguez-Lago, P Sendra Rumbeu, R Camargo Camero, D Hervías Cruz, G Molina Arriero, M Barreiro-de Acosta, D Acosta, Y Brenes, S Hermida, P Parra, A Garre, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i874-i876
Background Biological drugs used for IBD are detected in breast milk at a concentration below 10% of the maternal serum concentration and have therefore been considered as permitted drugs. However, warnings have recently been published regarding vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8aab631e9d00c3fa00eb5c2a40c5096a
https://doi.org/10.1093/ecco-jcc/jjac190.0874
https://doi.org/10.1093/ecco-jcc/jjac190.0874
Autor:
M Garcia-Alvarado, J Barrio, M Sierra-Ausin, L Arias, L Fernández-Salazar, A Fuentes Coronel, L Arias García, F J García-Alonso, M García-Prada, J Legido, J G Sánchez-Hernández, F Muñoz
Publikováno v:
Journal of Crohn's and Colitis. 16:i416-i418
Background Ustekinumab is an effective drug in Crohn′s Disease (CD) and most frequently used dose is subcutaneous (sc), 90 mg /, 8 weeks. With the usual sc doses (90 mg every, 8–12 weeks) some patients will only partially respond or experience se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02aab67af34e00577a7ce6f053bf9ecb
https://doi.org/10.1093/ecco-jcc/jjab232.560
https://doi.org/10.1093/ecco-jcc/jjab232.560
Autor:
M Chaparro, A Gutiérrez, C Calviño-Suárez, J M Huguet, M Calvo, M Aguas, R Camargo Camero, M Á de Jorge Turrión, D Hervías Cruz, P López Serrano, S Marín Pedrosa, P Martínez Montiel, M Rivero, R Vicente Lidón, L Arias García, M Arroyo, L Bujanda, M J Casanova, M Figueiras, A J Lucendo, N Manceñido Marcos, L Márquez, M D Martín-Arranz, M Boscá Watts, Y Ber, P Ramírez de la Piscina Urraca, I Pérez-Martínez, V Robles, A Ruiz-Cerulla, J M Vázquez Morón, L Madero, M Barreiro-de Acosta, M Capilla, I Vera Mendoza, D Acosta, Y Brenes, S Hermida, P Parra, M G Donday, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i491-i493
Background The safety of ustekinumab in pregnant patients with inflammatory bowel disease (IBD) and in their offspring has been barely studied. Aims Primary: To know the risk of serious adverse events (SAEs) in women exposed to ustekinumab during pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::937c68b486a568e6c69c84324094d726
https://doi.org/10.1093/ecco-jcc/jjab232.672
https://doi.org/10.1093/ecco-jcc/jjab232.672
Autor:
M I Iborra Colomino, A Garrido Marín, B Caballol Oliva, J M Huguet Malavés, L Arias García, F Mesonero Gismero, S J Fernández Prada, M M Boscá Watts, Á Ponferrada Díaz, X Calvet Calvo, A Gutiérrez Casbas, I Ordás Jiménez, L Ruiz Sanchez, B Sicilia Aladren, I Garcia de la Filia, E Domènech Morral, P Nos Mateu
Publikováno v:
Journal of Crohn's and Colitis. 17:i517-i518
Background Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) has been approved for inflammatory bowel disease (IBD). The aims of this study were to evaluate efficacy, safety, pharmacokinetics and patient experience follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c71a5fbe50c93ef27fa5894654b922c0
https://doi.org/10.1093/ecco-jcc/jjac190.0513
https://doi.org/10.1093/ecco-jcc/jjac190.0513
Autor:
Javier P. Gisbert, E. Leo Carnerero, I Rodríguez Lago, M T Diz-Lois Palomares, Saioa Rubio, María José Casanova, B Zúñiga de Mora-Figueroa, L Arias García, José María Huguet, M Figueira, Agnès Fernández-Clotet, N. Manceñido Marcos, I Pérez Martínez, R Vicente Lidón, R Rodríguez Insa, Iván Guerra, D. Hervías Cruz, P Martínez Montiel, P Ramírez de la Piscina Urraca, C Calviño Suárez, M Aguas, M Á de Jorge Turrión, L Ramos, A Ruiz Cerulla, A Gutiérrez Casbas, P Lopez Serrano, R Armesto, P Sendra Rumbeu, S Marín Pedrosa, G Molina Arriero, R. Camargo Camero, J M Vázquez Morón, C.A. Tardillo Marín, M. Rivero, C Suarez Ferrer, E Alfambra Cabrejas, Alfredo J. Lucendo, M. Chaparro, Luis Bujanda, M García Donday
Publikováno v:
Journal of Crohn's and Colitis. 15:S086-S088
Background Prospective registries are necessary to evaluate the safety of inflammatory bowel disease (IBD) treatment during pregnancy and in children in the long term. Aims The overall aim of DUMBO registry is to know the risk of serious adverse even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::983e15f9de378a53ed0f0ec910cc6672
https://doi.org/10.1093/ecco-jcc/jjab073.091
https://doi.org/10.1093/ecco-jcc/jjab073.091
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
I Chivato Martín-Falquina, L Alba Hernández, M L Arias García, E Badia Aranda, R M Saiz Chumillas, B Sicilia Aladrén
Publikováno v:
Journal of Crohn's and Colitis. 15:S400-S401
Background The efficacy of ustekinumab in patients with Crohn’s disease (CD) refractory to anti-TNF is worse than in anti-TNF naïve patients. Methods Retrospective study of patients with CD refractory or intolerant to TNF initiating ustekinumab be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe353ff7a5df09e00b387acb1253df31
https://doi.org/10.1093/ecco-jcc/jjab076.513
https://doi.org/10.1093/ecco-jcc/jjab076.513
Autor:
R de Francisco, M Mañosa, O. García‐Bosch, Xavier Calvet, E Sainz, M Piqueras, Jordi Gordillo, C Arajol, E. Domènech, P Delgado-Villena, E Sesé, A J Lucendo, David Busquets, Beatriz Sicilia, R. Mena, Javier P. Gisbert, Fernando Gomollón, M. Rivero, L. Sanromán, Matilde Navarro, M Aceituno, Alicia Algaba, María Chaparro, Miguel Minguez, R Ferreiro-Iglesias, L de Castro, Y Zabana Abdo, A Rodríguez-Pescador, Lucía Márquez, Maite Arroyo, R. Pajares, O. Benítez, E. Iglesias, Jordina Llaó, F Murciano, M Francisco, I Rodríguez-Lago, Morales, L Arias-García, Albert Villoria, Sabino Riestra, Maria Esteve, Teresa Angueira, Jordi Guardiola, M. García, Belén Beltrán, R. Vicente, Pablo Navarro
Publikováno v:
Journal of Crohn's and Colitis. 14:S614-S615
Background INFEII registry (ClinicalTrials.gov: NCT02904590) is a prospective study promoted by GETECCU to determine the incidence and risk factors of infection in an inception cohort of IBD patients. Despite preventive measures and recommendations o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::458c8db4c15678c527c7489d29db1a70
https://doi.org/10.1093/ecco-jcc/jjz203.902
https://doi.org/10.1093/ecco-jcc/jjz203.902
Autor:
C Rodríguez, P. Torres-Rodriguez, E Sesé, M David, Isabel Vera, X. Calvet, M Llorente, Morales, M Calafat, Patricia Camo, R. Pajares, R Sánchez-Aldehuelo, M Vela, F J Garcia-Alonso, M. Barreiro-de Acosta, L Arias-García, M Papo, Marisa Iborra, Luis Bujanda, L de Castro, Matilde Navarro, A. Rodríguez, José María Huguet, Jordina Llaó, I Rodríguez-Lago, A Castaño-García, J A Ferrer, Javier P. Gisbert, Fernando Gomollón, Marta Carrillo-Palau, E. Domènech, M González-Vivó, L Rufo, Míriam Mañosa, J M Benítez, P Ramírez de la Piscina, Pedro Almela, G Suris, M. Rivero, Fiorella Cañete
Publikováno v:
Journal of Crohn's and Colitis. 14:S463-S464
Background Three anti-TNFs (one intravenous and two subcutaneous) are licensed for the treatment of ulcerative colitis (UC). However, it is not known if the efficacy of a second anti-TNF changes on whether it is intravenous or subcutaneous; this coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a123bb9427ec6dc3f1a00da79c5dfcb
https://doi.org/10.1093/ecco-jcc/jjz203.672
https://doi.org/10.1093/ecco-jcc/jjz203.672